Ohr Pharmaceutical to Present at the 17th Annual BIO CEO & Investor Conference and Leerink Global Healthcare Conference in New York

NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference, and the Leerink Global Healthcare Conference.

Details of the Presentations:
Title: BIO CEO & Investor Conference
Date: Monday, February 9
Time: 4:00pm Eastern
Location: Louis XVI Room, Waldorf Astoria Hotel, New York City
Title: Leerink Global Healthcare Conference
Date: Wednesday, February 11
Time: 8:50am Eastern
Location: Carnegie Suite, Waldorf Astoria Hotel, New York City
Webcast: http://leerink.metameetings.com/confbook/healthcare15/directlink.php?ticker=OHRP

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead product, Squalamine, is currently being studied as an eye drop formulation (OR-102) in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program. Additional information on the company may be found at www.ohrpharmaceutical.com.

CONTACT: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 ir@ohrpharmaceutical.com LifeSci Advisors, LLC Michael Wood 646-597-6983 mwood@lifesciadvisors.comSource:Ohr Pharmaceutical, Inc.